metaShape Pharma presents at Longevity Investors Conference, 24–27 September 2024

The exclusive annual Longevity Investors Conference (LIC) was held for the fifth year in Gstaad, Switzerland between 24 and 27 September 2024. 

Bringing together some of the most prominent minds and investors in the longevity space, the conference agenda featured a combination of presentations on the longevity revolution in different industries, networking opportunities, wellness activities and a Startup Showcase. 

MetaShape Pharma was among the first four companies to be selected to present at the LIC Startup Showcase this year. The Company is pioneering therapeutics for age-related diseases by restoring the body’s ability to synthesise NAD+ (Nicotaminide Adenine Dinucleotide), an essential molecule that powers every living cell in our bodies to perform its vital functions. 

NAD+ decreases universally as we age, depriving our cells of the energy they need to carry out their normal physiological functions and leading to the onset of age-related diseases. MetaShape’s proprietary, small-molecule drug is proven in animal models to restore NAD+ to its prime levels in specific tissues, such as blood, brain and muscle tissue. Combining the reliability of a drug with safety established from Phase I and II studies with the ground-breaking potential of a new, patented chemical entity with a novel method of use, this candidate holds great promise for patients suffering from or at risk of cardiovascular, metabolic and neuro-degenerative conditions. 

Our technology was presented by our Founder-CEO, Thomas Mehrling, MD, PhD. You can watch the full video here: https://www.youtube.com/watch?v=z3sOq9-kIUw